Evidence map›Paper›PMID 34572762›Full record

ArticleCancers2021

Advances in the First Line Treatment of Pediatric Acute Myeloid Leukemia in the Polish Pediatric Leukemia and Lymphoma Study Group from 1983 to 2019.

Małgorzata Czogała, Walentyna Balwierz, Katarzyna Pawińska-Wąsikowska, Teofila Książek, Karolina Bukowska-Strakova, Wojciech Czogała, Barbara Sikorska-Fic, Michał Matysiak, Jolanta Skalska-Sadowska, Jacek Wachowiak and 25 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 15 institutions in 1 country.

Małgorzata CzogałaDepartment of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland.ORCID 0000-0003-1277-6810
Walentyna BalwierzDepartment of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland.
Katarzyna Pawińska-WąsikowskaDepartment of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland.
Teofila KsiążekDepartment of Medical Genetics, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland.
Karolina Bukowska-StrakovaDepartment of Clinical Immunology, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland.ORCID 0000-0001-9181-439X
Wojciech CzogałaDepartment of Pediatric Oncology and Hematology, University Children Hospital, 30-663 Krakow, Poland.
Barbara Sikorska-FicDepartment of Oncology, Pediatric Hematology, Transplantology and Pediatrics, Medical University of Warsaw, 02-091 Warsaw, Poland.
Michał MatysiakDepartment of Oncology, Pediatric Hematology, Transplantology and Pediatrics, Medical University of Warsaw, 02-091 Warsaw, Poland.
Jolanta Skalska-SadowskaDepartment of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, 60-572 Poznan, Poland.
Jacek WachowiakDepartment of Pediatric Oncology, Hematology and Transplantology, Poznan University of Medical Sciences, 60-572 Poznan, Poland.
Małgorzata Moj-HackemerDepartment of Bone Marrow Transplantation, Pediatric Oncology and Hematology, Wroclaw Medical University, 50-556 Wrocław, Poland.
Krzysztof KałwakDepartment of Bone Marrow Transplantation, Pediatric Oncology and Hematology, Wroclaw Medical University, 50-556 Wrocław, Poland.ORCID 0000-0003-1174-5799
Katarzyna Muszyńska-RosłanDepartment of Pediatric Oncology and Hematology, Medical University of Bialystok, 15-276 Bialystok, Poland.
Maryna Krawczuk-RybakDepartment of Pediatric Oncology and Hematology, Medical University of Bialystok, 15-276 Bialystok, Poland.ORCID 0000-0003-0899-5930
Dominik GrabowskiDepartment of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-090 Lublin, Poland.
Jerzy KowalczykDepartment of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-090 Lublin, Poland.
Lucyna Maciejka-KembłowskaDepartment of Pediatrics, Hematology and Oncology, Medical University of Gdansk, 80-211 Gdansk, Poland.
Ninela Irga-JaworskaDepartment of Pediatrics, Hematology and Oncology, Medical University of Gdansk, 80-211 Gdansk, Poland.
Katarzyna BobeffDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, 91-738 Lodz, Poland.
Wojciech MłynarskiDepartment of Pediatrics, Oncology and Hematology, Medical University of Lodz, 91-738 Lodz, Poland.ORCID 0000-0003-2714-5851
Renata TomaszewskaDepartment of Pediatrics Hematology and Oncology, Medical University of Silesia, 41-800 Zabrze, Poland.
Tomasz SzczepańskiDepartment of Pediatrics Hematology and Oncology, Medical University of Silesia, 41-800 Zabrze, Poland.ORCID 0000-0001-5336-261X
Agnieszka Chodała-GrzywaczDepartment of Pediatric Hematology and Oncology, Regional Polyclinic Hospital in Kielce, 25-736 Kielce, Poland.
Grażyna KarolczykDepartment of Pediatric Hematology and Oncology, Regional Polyclinic Hospital in Kielce, 25-736 Kielce, Poland.
Agnieszka Mizia-MalarzDepartment of Oncology, Hematology and Chemotherapy, Upper Silesia Children's Care Health Centre, Medical University of Silesia, 40-752 Katowice, Poland.ORCID 0000-0002-1984-5527
Katarzyna MyckoDepartment of Pediatrics and Hematology and Oncology, Province Children's Hospital, 10-561 Olsztyn, Poland.
Wanda BadowskaDepartment of Pediatrics and Hematology and Oncology, Province Children's Hospital, 10-561 Olsztyn, Poland.
Karolina ZielezińskaDepartment of Pediatrics, Hematology and Oncology, Pomeranian Medical University, 71-252 Szczecin, Poland.
Tomasz UrasińskiDepartment of Pediatrics, Hematology and Oncology, Pomeranian Medical University, 71-252 Szczecin, Poland.
Justyna Urbańska-RakusDepartment of Pediatrics, Hematology and Oncology, City Hospital, 41-500 Chorzow, Poland.
Małgorzata CiebieraDepartment of Pediatric Oncohematology, Clinical Province Hospital of Rzeszow, 35-301 Rzeszów, Poland.
Radosław ChaberDepartment of Pediatric Oncohematology, Clinical Province Hospital of Rzeszow, 35-301 Rzeszów, Poland.ORCID 0000-0002-6862-9142
Natalia BartoszewiczDepartment of Paediatrics, Haematology and Oncology, Nicolaus Copernicus University in Toruń Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.
Mariusz WysockiDepartment of Paediatrics, Haematology and Oncology, Nicolaus Copernicus University in Toruń Collegium Medicum in Bydgoszcz, 85-094 Bydgoszcz, Poland.
Szymon SkoczeńDepartment of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, 31-663 Krakow, Poland.ORCID 0000-0001-6867-2717
Jagiellonian University · PLMedical University of Silesia · PLGdańsk Medical University · PLKielce University of Technology · PLMedical University of Białystok · PLMedical University of Lodz · PLMedical University of Lublin · PLMedical University of Warsaw · PLNicolaus Copernicus University · PLPomeranian Medical University · PLPoznan University of Medical Sciences · PLUniversity of Computer Sciences and Economics in Olsztyn · PLUniversity of Rzeszów · PLWroclaw Medical University · PLUniversity School of Physical Education in Kraków · PL

Funding

Uniwersytet Jagielloński Collegium Medicum N41/DBS/000185
6 · The paper itself

Abstract

backgroundFrom 1983, standardized therapeutic protocols for pediatric acute myeloid leukemia (AML) based on the BFM group experience were introduced in Poland. We retrospectively analyzed the results of pediatric AML treatment in Poland from 1983 to 2019 (excluding promyelocytic, therapy-related, biphenotypic, and Down syndrome AML).

methodsThe study included 899 children suffering from AML treated with the following: AML-PPPLBC 83 (1983-1993,

resultsThe probability of three-year overall survival was 0.34 ± 0.03, 0.37 ± 0.05, 0.54 ± 0.04, 0.67 ± 0.03, and 0.75 ± 0.05; event-free survival was 0.31 ± 0.03, 0.34 ± 0.05, 0.44 ± 0.04, 0.53 ± 0.03, and 0.67 ± 0.05; and relapse-free survival was 0.52 ± 0.03, 0.65 ± 0.05, 0.58 ± 0.04, 0.66 ± 0.03, and 0.78 ± 0.05, respectively, in the subsequent periods. A systematic reduction of early deaths and deaths in remission was achieved, while the percentage of relapses decreased only in the last therapeutic period. Surprisingly good results were obtained in the group of patients treated with AML-BFM 2012 with unfavorable genetic abnormalities like KMT2A-MLLT10/t(10;11)(p12;q23) and DEK-NUP214/t(6;9)(p23;q24), while unsatisfactory outcomes were found in the patients with FLT3-ITD.

conclusionsThe use of standardized, systematically modified therapeutic protocols, with the successive consideration of genetic prognostic factors, and advances in supportive care led to a significant improvement in AML treatment outcomes over the last 40 years.

Indexed as

managementpediatric acute myeloid leukemiasurvival

Identifiers

PMID34572762
PMCPMC8472575
OpenAlexW3196899418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.